US OptionsDetailed Quotes
RPTX240517C5000
- 0.05
- 0.000.00%
15min DelayClose May 14 13:50 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover3253.28%IV53.03%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.1210Delta0.2154Gamma66.00Leverage Ratio-3.8616Theta0.0000Rho7.99Eff Leverage0.0001Vega
Repare Therapeutics Stock Discussion
Sign in to post a comment
$Repare Therapeutics(RPTX.US$ Repare Therapeutics (NASDAQ:RPTX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 136.14 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $52.40 million which beat the analyst consensus estimate of $38.40 million by 36.47 percent. This is a 822.93 percent increase over sales of $5.68 million the same period l...
2
2
$Repare Therapeutics(RPTX.US$
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
$Repare Therapeutics(RPTX.US$ Especially the MINOTAUR phase 1 Data release soon? 2024 Outlook:
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
•Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial. •Report initial ...
Repare Therapeutics' low P/S ratio is likely due to poor revenue performance and negative growth forecasts. The company's poor outlook compared to other industry players justifies its low P/S ratio.
1
The company's falling revenue and high cash burn relative to its market value are concerning. Despite a promising cash runway, the cash burn situation is considered a bit risky and causes some nervousness about the stock.
Repare Therapeutics' shrinking revenues and declining revenue forecast could challenge its P/S maintenance, possibly hindering significant share price growth. Its low P/S is acceptable to shareholders considering future revenue stagnation.
$Repare Therapeutics(RPTX.US$ Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
2
6
Gainers:
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
• $Repare Therapeutics(RPTX.US$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US$ +10.2% (In reaction ...
19
Gainers:
• $Actinium(ATNM.US$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics(AGLE.US$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $Grid Dynamics(GDYN.US$ +5% (expands in Europe ceases operations in Russia)
• $Artisan Partners Asset Management(APAM.US$ +4....
• $Actinium(ATNM.US$ +30.81% (Actinum Pharma and Immedica to commercialize lomab-B (1311 apamistamab) in Europe the Middle East and North Africa)
• $Aeglea BioTherapeutics(AGLE.US$ +18.11% (presents additional data from PEACE phase 3 study of Pegzilarginase; submits BLA to FDA for Pegzilarginase)
• $Grid Dynamics(GDYN.US$ +5% (expands in Europe ceases operations in Russia)
• $Artisan Partners Asset Management(APAM.US$ +4....
12
5
2022. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. All Rights Reserved. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. Portfolio results are unaudited and based on varying investment expiration dates. Terms of Service | Privacy Policy
ColumnsARK latest trades
Note that ARK has been adding more of RHHBY, REGN and TDOC for over a month at least
$Teladoc Health(TDOC.US$ $Repare Therapeutics(RPTX.US$ $ROCHE HOLDING AG(RHHBY.US$ $Regeneron Pharmaceuticals(REGN.US$ $Novartis AG(NVS.US$ $Zoom Video Communications(ZM.US$ $Tesla(TSLA.US$
$Teladoc Health(TDOC.US$ $Repare Therapeutics(RPTX.US$ $ROCHE HOLDING AG(RHHBY.US$ $Regeneron Pharmaceuticals(REGN.US$ $Novartis AG(NVS.US$ $Zoom Video Communications(ZM.US$ $Tesla(TSLA.US$
6
No comment yet
whaleeeeeeeeeeeeeeee : why izzit tanking wtheck
TrytosaveabitOP whaleeeeeeeeeeeeeeee: Not enough buy side pressure! Sells from shorts and some profit takers is just putting to much downward pressure with not enough volume to push back! GL